B+
Bull case
25%
Probability
Target price
$9.50
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
STTK
Shattuck LabsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The bull case is still a monitoring-style biotech setup: March company disclosures pointed to a near-complete Phase 1 program, Q2 2026 human data, a possible Q3 2026 Phase 2 Crohn's start, and runway guidance into 2029 that included first-quarter ATM proceeds and warrant assumptions [#8-K-2026-03-05]. If the Phase 1 package shows clean safety, durable receptor occupancy, and a credible path into Crohn's disease, the stock could move above the current median target baseline, but the weak direct peer set limits confidence in any valuation read-through.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +13.6.
What can break
No new Q1 2026 company earnings filing was located in SEC sources checked on May 4, 2026, leaving surprise, guidance, and immediate post-print reaction evidence unavailable for this T+1 run.
Momentum
68
Value
41
Sentiment
76
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.25 · Bull $9.50 · Bear $4.50Analysis 2026-05-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $15.25
Why
Momentum68 · Δ7d +3.3
Value41 · Δ7d 0.0
Sentiment76 · Δ7d +13.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +13.6.
Contradictions & invalidation
- • No new Q1 2026 company earnings filing was located in SEC sources checked on May 4, 2026, leaving surprise, guidance, and immediate post-print reaction evidence unavailable for this T+1 run.
- • Runway guidance into 2029 in the March update included first-quarter ATM proceeds and assumed full exercise of outstanding warrants, so financing and dilution remain part of the risk picture rather than a fully removed concern [#8-K-2026-03-05].
- • For this May 4, 2026 T+1 follow-up, a new Q1 2026 earnings release, 8-K, or 10-Q was not located in SEC company sources checked, so earnings surprise, guidance revision, and analyst target-reset evidence are unavailable.
Catalyst clock
2026-06-30
SL-325 Phase 1 data still frames the main re-rating window in Q2 2026
Lead driver: Sentiment · See AI snapshot
Momentum
68
9% active weight
Current posture
7d trendImproving
Δ7d
+3.3
Δ21d
-26.6
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
76
62% active weight
Current posture
7d trendImproving
Δ7d
+13.6
Δ21d
+19.6
Why this grade
Composite grade B. Momentum 68.0 / Value 41.2 / Sentiment 76.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-04. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$7.25
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$741.68M
Beta
1.53
Shares Out
90.37M
P/E (TTM) · Derived
-11.7
P/S (TTM)
246.16
P/FCF (TTM) · Derived
-20.23
Rev YoY
-66.6%
EPS YoY
-52.2%
Gross Margin
-256.5%
Op Margin
-5777.8%
Net Debt
-$75.64M
Current Ratio
27.59
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data